{"id":"corticosteroid-or-pentoxifylline","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (corticosteroid-related immunosuppression)"},{"rate":null,"effect":"Gastrointestinal upset (pentoxifylline)"},{"rate":null,"effect":"Hyperglycemia (corticosteroid-related)"},{"rate":null,"effect":"Insomnia or mood changes (corticosteroid-related)"}]},"_chembl":{"chemblId":"CHEMBL628","moleculeType":"Small molecule","molecularWeight":"278.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Corticosteroids work by binding glucocorticoid receptors to inhibit pro-inflammatory gene transcription and immune cell activation. Pentoxifylline is a phosphodiesterase inhibitor that reduces TNF-α and other inflammatory mediators while improving microcirculatory blood flow. Together, they provide complementary anti-inflammatory and rheological benefits.","oneSentence":"This combination therapy uses corticosteroids to suppress inflammatory immune responses and pentoxifylline to improve blood flow and reduce inflammatory cytokine production.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:45.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory or immune-mediated conditions under investigation in phase 3 trials"}]},"trialDetails":[{"nctId":"NCT03104985","phase":"NA","title":"LLLT of Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency","status":"COMPLETED","sponsor":"Research Center Matrix","startDate":"2013-05","conditions":"Trophic Ulcers, Chronic Venous Insufficiency","enrollment":68},{"nctId":"NCT02485106","phase":"PHASE3","title":"Rifaximin Use in Severe Alcoholic Hepatitis","status":"UNKNOWN","sponsor":"Saint Vincent's Hospital, Korea","startDate":"2015-07","conditions":"Severe Alcoholic Hepatitis","enrollment":170},{"nctId":"NCT00771446","phase":"PHASE1, PHASE2","title":"Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency","status":"COMPLETED","sponsor":"Vital Therapies, Inc.","startDate":"2008-10","conditions":"Acute Hepatitis, Chronic Hepatitis","enrollment":18},{"nctId":"NCT00354731","phase":"PHASE3","title":"Efficacy of Pentoxifylline on Primary Nephrotic Syndrome","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-08","conditions":"Nephrotic Syndrome","enrollment":62},{"nctId":"NCT00354198","phase":"PHASE3","title":"Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2006-08","conditions":"Glomerulonephritis","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":413447,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Corticosteroid or pentoxifylline","genericName":"Corticosteroid or pentoxifylline","companyName":"Saint Vincent's Hospital, Korea","companyId":"saint-vincent-s-hospital-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses corticosteroids to suppress inflammatory immune responses and pentoxifylline to improve blood flow and reduce inflammatory cytokine production. Used for Inflammatory or immune-mediated conditions under investigation in phase 3 trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}